succinate dehydrogenase complex subunit D pseudogene 5Genealiases: []
Q-omics provides the consensus-scored SDHDP5 profile across patient tissues and cancer cell-line models. SDHDP5 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SDHDP5 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, SDHDP5 RNA expression shows 6,160 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, THCA, and STAD as cancer lineages where SDHDP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHDP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHDP5 survival associations across molecular data types. SDHDP5 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHDP5 RNA expression–survival associations across cancer types. High SDHDP5 expression shows unfavorable associations in LIHC, BLCA, UVM, LGG, UCEC and CHOL. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SDHDP5 RNA expression.
This table summarizes SDHDP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SDHDP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHDP5 shows lower tumor expression in THCA and higher tumor expression in KIRP. The THCA box plot shows higher SDHDP5 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p = .045).
This table shows molecular features associated with SDHDP5 in patient tissues and cancer cell lines. In patient samples, SDHDP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
